key: cord-0840223-mv4267zz authors: Tavana, Madjid; Govindan, Kannan; Nasr, Arash Khalili; Heidary, Mohammad Saeed; Mina, Hassan title: A mathematical programming approach for equitable COVID-19 vaccine distribution in developing countries date: 2021-06-03 journal: Ann Oper Res DOI: 10.1007/s10479-021-04130-z sha: 639a3f25f710811da636c7a7fbc0c1b66b17f285 doc_id: 840223 cord_uid: mv4267zz Developing countries scramble to contain and mitigate the spread of coronavirus disease 2019 (COVID-19), and world leaders demand equitable distribution of vaccines to trigger economic recovery. Although numerous strategies, including education, quarantine, and immunization, have been used to control COVID-19, the best method to curb this disease is vaccination. Due to the high demand for COVID 19 vaccine, developing countries must carefully identify and prioritize vulnerable populations and rationalize the vaccine allocation process. This study presents a mixed-integer linear programming model for equitable COVID-19 vaccine distribution in developing countries. Vaccines are grouped into cold, very cold, and ultra-cold categories where specific refrigeration is required for their storage and distribution. The possibility of storage for future periods, facing a shortage, budgetary considerations, manufacturer selection, order allocation, time-dependent capacities, and grouping of the heterogeneous population are among the practical assumptions in the proposed approach. Real-world data is used to demonstrate the efficiency and effectiveness of the mathematical programming approach proposed in this study. The Developing Countries Vaccine Manufacturers Network (DCVMN) is a public-health agency representing vaccine manufacturers from emerging countries. The DCVMN is committed to protecting all people through research and development activities and manufacturing and distributing coronavirus disease 2019 vaccines to developing countries (Pagliusi et al., 2020) . COVID-19 has stressed the importance of preventing pulmonary infections and stopping the pandemic with vaccinations (Dinleyici et al., 2020) . The World Health Organization (WHO) statistics show that nearly 84,000,000 cases of the virus have been identified worldwide by the end of 2020, and about 1,800,000 people have lost their lives (https:// coron avirus. jhu. edu). The coronavirus outbreak has drastically changed global social norms and has brought about disruptions in health services provision (Chandir et al., 2020) . Since the beginning of the disease outbreak, various strategies such as border closure, social distance, widespread testing, and homestay have been proposed by statesmen, the WHO, and other relevant centers to reduce the virus's spread and cut its transmission chain (Coudeville et al., 2020) . Some researchers, such as Govindan et al. (2020) , have tried to reduce this disease's prevalence by classifying people in the community and offering solutions to each class of people. Although these protective measures are crucial to managing this disease, vaccination is a critical defensive behavior to control and eradicate it (Reiter et al., 2020) . More than 100 companies are developing the COVID-19 vaccine worldwide, some of which are placed in phase III trials (Degeling et al., 2020) . With the mass production of the vaccine, demand is expected to outstrip supply in the early stages. Therefore, the vaccine distribution process will be of great importance. Government budget constraints, cold supply chain management, prioritization of people in the community, and waiting time for receiving vaccines are essential factors affecting vaccine distribution worldwide. Therefore, this study develops a mixed-integer linear programming (MILP) model for equitable COVID-19 vaccine distribution considering the factors mentioned above. Duijzer et al. (2018) examined the literature on the vaccine supply chain. They categorized these studies into the product, production, allocation, and distribution modeling groups by combining the WHO's priorities for creating a robust and flexible vaccine supply chain with an operations research perspective. Similarly, De Boeck et al. (2019) studied the vaccine distribution studies in low-and middle-income countries. They identified several problems that had received little or no attention in the operations research literature. They found operations researchers heavily concentrate on the strategic decisions in vaccine distribution chains and, to a lesser extent, tactical and operational decisions. Hovav and Tsadikovich (2015) used mathematical programming and proposed an optimization model to design a healthcare supply chain to control influenza vaccines' distribution and inventory control. Saif and Elhedhli (2016) developed a cold supply chain for the distribution and inventory management of vaccines considering environmental issues. For this purpose, they proposed a mixed-integer programming (MIP) model to minimize total costs and used a Lagrangian decomposition algorithm to solve the proposed model. Lim et al. (2019) proposed a MIP model for redesigning a cold supply chain for vaccine distribution by considering the location problem and limitations. They developed a hybrid heuristic algorithm for large-scale problem-solving and validated their model using several African countries' data. A bi-objective model was developed by Zandkarimkhani et al. (2020) to design a perishable pharmaceutical supply chain network and minimize total costs and lost demands. They used an integrated inventory-location-routing problem and developed a chain to distribute Avonex (prefilled syringe for multiple sclerosis disease). One of the issues that should be considered in developing a vaccine distribution supply chain is the ambient temperature in which the vaccines are stored and transported. The transportation of vaccines at unfavorable temperatures has led to adverse events, especially in developing countries. Hence, Lin et al. (2020) proposed a model to solve this problem by implementing inspection strategies. Their intended chain includes distributors and retailers, and they analyze inspection policies of vaccines' transportation in the cold supply chain. Gamchi et al. (2020) presented a novel bi-objective model using the susceptibleinfected-recovered epidemic model and vehicle routing problem for vaccine distribution. Their model simultaneously minimizes social costs and the costs of operating vehicles and groups of people in the community. They validated their model using data from a cholera vaccine distribution chain. Yang et al. (2020) developed a MIP model for vaccine distribution in low-and middle-income countries in line with the WHO Expanded Program on Immunization (EPI). Their model aims to minimize total costs with validation using data from a vaccine distribution chain in African countries. Bulula et al. (2020) used a microcosting approach to analyze costs in the vaccine supply chain. They showed the delegation of the vaccine supply chain's responsibilities from the medical stores to the EPI would lead to a 27% reduction in the vaccine distribution and storage costs. The trade-offs between the equitable allocation of resources have been studied in energy (Sasse & Trutnevyte, 2019) , bicycle-sharing (Conrow et al., 2018) , and food donation (Fianu & Davis, 2018; Orgut et al., 2016 Orgut et al., , 2017 . Equitable distribution of resources must consider a fair sharing of the resources among recipients; however, studies emphasizing equitable distribution of resources are limited (Fianu & Davis, 2018) . Equity and fairness are among the most critical issues to be considered in the vaccine distribution chain (Abila et al., 2020) . In this regard, Enayati and Özaltın (2020) proposed a mathematical programming model for equitable influenza vaccine distribution. They divided the population into several subgroups and prevented the epidemic outbreaks by allocating the necessary vaccines to each subgroup equitably. Rastegar et al. (2021) went one step further and developed a MILP model for equitable influenza vaccine distribution by considering the location-inventory problem under pandemic COVID-19 conditions. The possibility of storage for future periods, being faced with a shortage, and budget constraints are among the practical assumptions considered in this research. They proposed a novel objective function to consider the concept of equitable distribution. They then evaluated their proposed model's performance using data from an influenza vaccine distribution chain in Iran. The remainder of this paper is organized as follows. In Sect. 2, we present our motivation and contributions. The proposed mathematical model is presented in Sect. 3. In Sect. 4, we present a case study to demonstrate the applicability of the method proposed in this study. A sensitivity analysis is conducted in Sect. 5 to exhibit the efficacy and robustness of our vaccine distribution method. We conclude the paper with our conclusions and future research directions in Sect. 6. A review of the vaccine distribution literature shows the research in this field is in its infancy. Some researchers, such as De Boeck et al. (2019) and Corey et al. (2020) , have studied strategic and managerial approaches to vaccine distribution. Other researchers such as Gamchi et al. (2020) , Yang et al. (2020) , and Rastegar et al. (2021) have proposed mathematical models for vaccine distribution and supply chain network optimization. Supply chains for vaccine distribution require unique features. For example, some vaccine distribution requires a cold or very cold supply chain (i.e., Gamchi et al., 2020; Lim et al., 2019; Yang et al., 2020) . Other vaccine distributions may require waiting time considerations in the supply chain (i.e., Gamchi et al., 2020) . There is also the concern for fair and equitable access to vaccines. Sometimes it is impossible to provide vaccines for all members of society. Therefore, equitable distribution becomes a critical consideration and assumption in vaccine distribution networks (Enayati & Özaltın, 2020; Rastegar et al., 2021) . Distribution of COVID-19 vaccines requires cold, very cold, and ultra-cold refrigeration. Waiting time to receive the vaccines from manufacturers also directly affects the delivery of vaccines to the public. This study presents the first mathematical model for equitable COVID-19 vaccine distribution considering time-dependent capacity and triple refrigeration requirement (i.e., cold, very cold, and ultra-cold). Rastegar et al. (2021) proposed a mathematical model for equitable influenza vaccine distribution. The current study presents a MILP model for equitable distribution of the COVID-19 vaccines. The model proposed by Rastegar et al. (2021) is a single-product model. However, the current study addresses the need for a multi-product model for COVID-19 vaccine distribution requiring cold, very cold, and ultra-cold refrigeration. Moreover, this study considers multiple cold supply chains with varying refrigeration requirements. This capability does not exist in the model proposed by Rastegar et al. (2021) . The ordering and delivery times of vaccines can vary in the current study because of the potential waiting time between ordering and receiving the vaccines. However, the model proposed by Rastegar et al. (2021) does not consider waiting time because vaccines are provided in the same period they are ordered. In summary, the contributions of this study are to (i) introduce a location-inventory MILP model for a fair and equitable COVID-19 vaccine distribution in developing countries; (ii) propose a model to consider cold, very cold, and ultra-cold supply chain network design and; (iii) take into consideration an equitable vaccine distribution model capable of manufacturer selection, order allocation, capacity planning, and waiting time management; and (iv) validating the proposed model with real-world data. Satisfying the global demand for COVID-19 vaccines is not a short-term problem due to limited production and supply. Consequently, vaccine delivery is subject to the waiting time. This study presents a MILP model for equitable COVID-19 vaccine distribution in developing countries by considering the location-inventory problem. In addition to limited production and supply constraints, the refrigeration requirement for the COVID-19 vaccine and the need for cold, very cold, and ultra-cold supply chains is a huge hurdle in developing countries. Furthermore, the need for grouping and prioritizing the population is another added complexity for the COVIS-19 vaccine distribution. The proposed model is considered a budget constraint and allows the applicant country to make the following customizations to the model: Which manufacturer should be selected? What period should the vaccine be ordered to the manufacturer, and how much? What is the waiting time for each manufacturer? Which distribution centers are needed? Which distribution centers need ultra-cold refrigeration equipment? How many vaccines should be transferred from distribution centers to warehouses in different states in each period? How many vaccines should be stored in the state warehouses in each period? How many vaccines should be allocated to each group in each state and period? To better understand the problem under study, the assumptions of the proposed model are given as follows: • The proposed model is considered as multi-product and multi-period. • The model determines the location of distribution centers. • The established distribution centers can handle cold and very cold refrigeration. • Ultra-cold refrigeration can only be installed in previously established distribution centers equipped with very cold refrigeration. • An order can be placed after an existing order is received. • One order can be placed with each manufacturer in each period. • Time-dependent capacity is considered for the manufacturers. • Distribution centers are capacitated. • Each manufacturer produces only one type of vaccine. • The possibility of storage in the state warehouses for future periods is considered. • The possibility of facing a shortage is considered. The proposed model's objective function is derived from the model presented by Rastegar et al. (2021) that focuses on the equitable distribution of the vaccine. In this objective function, vaccines are distributed based on maximizing the minimum delivery-to-demand ratio. Constraint (2) ensures that each group receives the vaccine at least up to the coverage rate. Constraints (3) and (4) are related to the inventory balance in the state warehouses in period 1 and the periods greater than one, respectively. (1) Not exceeding the capacity of vaccine manufacturers has been shown by constraint (5). Not exceeding the distribution centers' capacity of cold, very cold, and ultra-cold refrigeration is guaranteed in constraints (6) to (88), respectively. The condition for the purchase of vaccines from manufacturers is that the order should be placed with the manufacturer. This condition is considered in constraint (9). According to constraint (10), if a distribution center with proper equipment for cold refrigeration vaccines has not been set up, it will not receive orders from manufacturers. Similarly, based on the constraint (11), if a distribution center has not been equipped with very cold and ultra-cold refrigeration, it will not receive orders from manufacturers. One order can be placed with each manufacturer in each period. This condition is satisfied by constraint (12). According to the location conditions, if a distribution center with proper equipment for cold refrigeration vaccines has not been set up, it will not be allowed to send cold refrigeration vaccines to the states' warehouses. This condition is considered in (13). Also, if a distribution center equipped with very cold refrigeration has not been set up, it will not be allowed to send very cold refrigeration vaccines to the states' warehouses. Similarly, suppose a distribution center equipped with ultra-cold refrigeration has not been set up. In that case, that distribution center will not send ultra-cold vaccines to the states' warehouses. These conditions are considered in constraints (14) and (15), respectively. Moreover, there is no possibility of setting up the distribution centers equipped with ultra-cold refrigeration until the distribution centers equipped with very cold refrigeration are set up. This condition is also expressed by constraint (16). The amount of vaccines delivered to each distribution center in each period is calculated by constraint (14). Constraint (15) is responsible for establishing the inventory balance in distribution centers. As long as the order is being processed (i.e., it has not yet been delivered to the distribution center), it will not be possible to place a new order with that manufacturer. This condition is satisfied by constraint (16). In all the constraints of the proposed model, the ordering time should always be less than or equal to the delivery time. Constraint (17) has been used to meet this condition. In the end, constraint (18) states that the supply chain's total costs should not exceed the available budget. These costs include ordering cost to manufacturers, set-up cost of distribution centers for cold refrigeration, very cold refrigeration, and ultra-cold refrigeration vaccines, purchasing cost of vaccines, transportation cost from manufacturers' location to distribution centers, transportation cost from distribution centers to state warehouses, and holding cost at the state warehouses. As can be seen, the objective function of the proposed model is nonlinear. To linearize it, we define a new free variable ( ) and replace it with Min . Therefore, the following holds true: Based on Eq. (19), the following formula always holds true: Therefore, based on Eq. (19) and Eq. (20), the proposed nonlinear model is converted to a linear one as follows: Constraints (2) to (18). This section demonstrates the applicability of the model proposed in this study with the data obtained from the Ministry of Health and Family Welfare (MOHFW) in India. COVID-19 vaccines have been discovered not so long ago, and, thereby, adequate information and data on their distribution are not yet fully available and accessible. As a result, some data, including transportation costs, vaccine prices, and manufacturers' capacities, are simulated based on the MOHFW's preliminary estimations. As in the study carried out by Rastegar et al. (2021) , the heterogeneous population in this study is also divided into eight groups. The group numbers are not representative of priorities. These group numbers simply identify a segment of the population: • Group (1): infants and toddlers ages 6-35 months, • Group (2): pregnant women with pre-existing medical conditions, • Group (3): adults aged 65 years and older with pre-existing medical conditions, • Group (4): critical healthcare providers and first responders, • Group (5): pregnant women without pre-existing conditions, • Group (6): adults aged 65 years and older without pre-existing medical conditions, • Group (7): people with pre-existing medical conditions, and • Group (8): other people. This study considers five vaccine types. Vaccine types 1 and 2 require ultra-cold refrigeration (− 70 °C ± 10 °C), vaccine types 3 and 4 require very cold refrigeration (− 25 °C to − 15 °C), and vaccine type 5 requires cold refrigeration (− 8 °C to − 2 °C). The vaccines are purchased from manufacturers outside India and are then transported to distribution centers. Afterward, vaccines are shipped to different distribution centers and distributed equitably among multiple warehouses in multiple states according to demand (See Fig. 1) . We should note data such as the demand for each group in each state, holding cost for the vaccines, coverage rate, and transportation cost between distribution centers and states have been extracted from historical data proposed by the MOHFW. Furthermore, the MOHFW's estimated budget for vaccine purchase and distribution is 4.5 billion dollars. Table 1 presents the vaccine manufacturers' capacities. Additional data is provided in Appendix A (Tables 8, 9, 10, 11, 12, 13, 14, 15 and 16) . The 7,500,000 in the first row of Table 1 indicates that if the order is placed to manufacturer 1 in period 1, the manufacturer will deliver a maximum of 7,500,000 doses of vaccines in period 3. The proposed model was run with the described data in GAMS software using CPLEX solver. The obtained results are as follows: • Distribution centers in Patna, Bhopal, and Hyderabad were set up to distribute the vaccines. Patna and Bhopal distribution centers can distribute vaccines requiring cold, very 1 1 0 0 7,500,000 10,000,000 15,000,000 19,000,000 25,000,000 30,000,000 1 2 0 0 3,000,000 7,000,000 11,000,000 15,000,000 20,000,000 25,000,000 1 3 0 0 0 5,000,000 9,000,000 13,000,000 18,000,000 22,000,000 1 4 0 0 0 0 5,000,000 9,000,000 15,000,000 20,000,000 1 5 0 0 0 0 0 7,500,000 12,500,000 17,500,000 1 6 0 0 0 0 0 0 6,000,000 10,000,000 1 7 0 0 0 0 0 0 0 15,000,000 1 8 0 0 0 0 0 0 0 2,500,000 2 1 0 6,000,000 15,000,000 20,000,000 28,000,000 32,000,000 40,000,000 60,000,000 2 2 0 0 10,000,000 14,000,000 20,500,000 27,000,000 35,000,000 42,000,000 2 3 0 0 0 8,000,000 13,500,000 20,000,000 27,500,000 34,000,000 2 4 0 0 0 0 12,000,000 18,000,000 25,500,000 32,000,000 2 5 0 0 0 0 0 9,500,000 16,000,000 30,000,000 2 6 0 0 0 0 0 0 10,000,000 25,000,000 2 7 0 0 0 0 0 0 0 20,000,000 2 8 0 0 0 0 0 0 0 0 3 1 0 4,000,000 7,000,000 13,000,000 20,000,000 25,000,000 30,000,000 35,000,000 3 2 0 0 4,000,000 8,000,000 15,000,000 20,000,000 25,000,000 30,000,000 3 3 0 0 0 5,000,000 9,000,000 15,000,000 21,000,000 25,000,000 3 4 0 0 0 0 4,000,000 8,000,000 14,000,000 19,000,000 3 5 0 0 0 0 0 4,000,000 8,000,000 15,000,000 3 6 0 0 0 0 0 0 6,000,000 9,000,000 3 7 0 0 0 0 0 0 0 5,000,000 3 8 0 0 0 0 0 0 0 0 4 1 0 4,000,000 7,000,000 11,000,000 17,500,000 21,000,000 27,500,000 34,000,000 4 2 0 0 1,500,000 3,000,000 6,000,000 8,750,000 11,250,000 15,500,000 4 3 0 0 0 2,000,000 3,750,000 6,000,000 8,750,000 11,500,000 4 4 0 0 0 0 1,500,000 3,000,000 4,500,000 6,000,000 4 5 0 0 0 0 0 5,000,000 8,000,000 11,000,000 4 6 0 0 0 0 0 0 2,000,000 5,250,000 4 7 0 0 0 0 0 0 0 6,000,000 4 8 0 0 0 0 0 0 0 0 5 1 0 5,000,000 9,000,000 14,000,000 18,000,000 25,000,000 30,000,000 36,000,000 5 2 0 0 4,000,000 7,500,000 12,000,000 16,000,000 22,000,000 27,000,000 5 3 0 0 0 4,000,000 7,500,000 13,000,000 18,000,000 24,000,000 5 4 0 0 0 0 4,000,000 8,000,000 13,000,000 20,000,000 5 5 0 0 0 0 0 5,000,000 10,000,000 16,000,000 5 6 0 0 0 0 0 0 6,000,000 12,000,000 5 7 0 0 0 0 0 0 0 7,000,000 5 8 0 0 0 0 0 0 0 0 cold, and ultra-cold refrigeration, whereas Hyderabad distribution center can distribute vaccines requiring cold and very cold refrigeration. • Orders are placed with all five manufacturers. Patna and Bhopal distribution centers receive vaccines from all five manufacturers, but vaccines are purchased only from manufacturers 3, 4, and 5 for the Hyderabad distribution center. • With the available budget of 4.5 billion dollars, 186,096,615 doses of COVID-19 vaccines were purchased. The optimal doses of vaccines ordered to each manufacturer and the optimal doses of vaccines delivered by each distribution center are shown in Tables 2 and 3, respectively. For example, 7,500,000 in the first row of Table 2 indicates that distribution center 1 (Patna) has ordered type 1 vaccine in period 1 and received 7.5 million doses of vaccines in period 3. The numbers included in Table 3 indicate the optimal doses of vaccines delivered to each distribution center in different periods. For example, 11,123,260 in the first row and last column of this table suggests that 11,123,260 doses of vaccine type 1 have been delivered to the Patna distribution center in period 8. Table 2 shows that this order has been placed in period 7. • The optimal doses of vaccines assigned to group 1 are given in Table 4 . Similarly, in Appendix B (Tables 17, 18 , 19, 20, 21, 22 and 23), the optimal doses of vaccines allocated to groups 2 to 8 are presented, respectively. • The optimal doses of vaccines shipped from distribution centers to the state warehouses in each period are shown in Table 5 . • Finally, Table 6 presents the number of vaccine doses stored in the state warehouses in each period. For example, 3,967,289 in the first row of Table 5 represents the number of type 1 vaccine doses shipped from Patna distribution center to state 1 (Uttar Pradesh) in period 3. Figure 2 presents the total doses of vaccines delivered to each state. The following items have been depicted in Fig. 3 to provide a more accurate interpretation of the obtained result: the optimal doses of vaccines purchased from each manufacturer by the distribution centers, the optimal doses of vaccines assigned to the Kerala State to each group in each period, and the optimal doses of vaccines shipped from the Hyderabad distribution center to the Kerala State in each period. The results presented in Fig. 3 show that a total of 186,096,615 double-dose vaccines have been purchased from each of the five manufacturers, where 85,096,615 vaccines required ultra-cold refrigeration, 66,000,000 vaccines required very cold refrigeration, and the remainder required cold refrigeration. From the total purchased vaccine, 111,668,835 and 44,965,339 double-dose vaccines have been allocated to the Patna and Bhopal distribution centers, respectively. The remaining 29,462,441 doubledose vaccines have been allocated to the Hyderabad distribution center. In addition, the equitable vaccine distribution in Kerala State is depicted in this figure. 1,397 ,340 double-dose vaccines are transferred to this state from the Hyderabad distribution center in period 4, out of which 1,387,340 vaccines were assigned to group 1, and the remaining 9793 vaccines were allocated to group 2. Similarly, vaccines assigned to each group in periods 5 to 8 are shown in this figure. It is worth noting again some parameters, including transportation costs, vaccine prices, and manufacturing capacities, have Table 2 The optimal doses of vaccines delivered to distribution centers in each period In this section, we study the performance of the model proposed in this study according to various budgetary constraints. We begin the sensitivity analysis by increasing (decreasing) the total budget and expect that the total doses of the purchased vaccine will increase (decrease) accordingly. For this purpose, we consider nine budgeting scenarios and calculate the total doses of the purchased vaccine for each scenario. The total doses of purchased vaccines for these scenarios are presented in Table 7 and Fig. 4 . As shown in Table 7 and Fig. 4 , as the budget amount increases (i.e., scenarios 6 to 9), the total doses of the purchased vaccine increase, and as the budget amount decreases (i.e., scenarios 4 to 1), the total doses of the purchased vaccine decreased. The results are logical and meet our expectations of the proposed model behavior. This sensitivity analysis confirms the applicability and logical performance of the model. This study proposed a mathematical programming model for equitable COVID-19 vaccine distribution in developing countries in the context of a location-inventory problem, considering the concepts of equity and taking into account the needs for cold, very cold, and ultra-cold supply chains. This model is the general form of Rastegar et al.'s (2021) model that provides the possibility of distributing vaccines requiring cold, very cold, and Table 4 The optimal doses of vaccines assigned to group 1 in each period Data from a case study in India is used to validate the practical application of the proposed model. The results showed that with 4.5 billion dollars, the Indian government could purchase over 186 million double-dose COVID-19 vaccines, including over 85 million for ultra-cold, 66 million for very cold, and 35 million double-doses for cold supply chains. Finally, sensitivity analysis was used to confirm the applicability and logical performance of the model. This study has proposed an operational model with strategic consideration under certainty for equitable COVID-19 vaccine distribution. Life is full of uncertainty, and failing to fully consider operational uncertainties can have detrimental consequences in any operations, including vaccination efforts in developing countries. Future research is needed to study some of our operational assumptions under uncertain conditions. In addition, more complex models with additional objective functions (i.e., emission reduction) can improve the real-world applicability of the vaccine distribution model proposed in this study. Future advanced analytics research is needed to coordinate manufacturing and distribution with healthcare providers and pharmacies to deploy vaccines more effectively and efficiently through specialized supply chain networks. Fig. 2 The total doses of vaccines allocated to each state Fig. 4 Total doses of the purchased vaccine for each scenario Coverage rate ( g ) 0.75 0.9 0.85 1 0.7 0.6 0.75 0.05 See Tables 17, 18, 19 , 20, 21, 22 and 23. Table 17 The optimal doses of vaccines allocated to group 2 in each period Table 18 The optimal doses of vaccines allocated to group 3 in each period 5 3 14 0 0 0 0 0 88,345 5 3 16 0 0 0 0 0 175,129 5 3 20 0 0 0 0 0 17,569 5 3 22 0 0 0 0 0 8268 5 3 23 0 0 0 0 0 21,922 5 3 25 0 0 0 14,949 0 0 5 3 26 0 0 0 0 0 11,236 5 3 29 0 0 0 5539 0 0 5 3 30 0 0 0 0 1385 0 5 3 31 0 0 0 0 0 3237 5 3 33 0 1804 0 0 0 0 5 3 34 0 0 0 0 826 0 5 3 35 0 0 0 0 0 1397 5 3 36 0 0 0 0 0 94 Table 19 The optimal doses of vaccines allocated to group 4 in each period Table 21 The optimal doses of vaccines allocated to group 6 in each period Table 22 The optimal doses of vaccines allocated to group 7 in each period Table 23 The optimal doses of vaccines allocated to group 8 in each period We need to start thinking about promoting the demand, uptake, and equitable distribution of COVID-19 vaccines NOW! Public Health in Practice Vaccine storage and distribution between expanded program on immunization and medical store department in Tanzania: A cost-minimization analysis Impact of COVID-19 pandemic response on uptake of routine immunizations in Sindh, Pakistan: an analysis of provincial electronic immunization registry data An optimization approach for equitable bicycle share station siting A strategic approach to COVID-19 vaccine R&D Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry Vaccine distribution chains in low-and middleincome countries: A literature review Priority allocation of pandemic influenza vaccines in Australia-Recommendations of 3 community juries Vaccines and routine immunization strategies during the COVID-19 pandemic Literature review: The vaccine supply chain Optimal influenza vaccine distribution with equity A Markov decision process model for equitable distribution of supplies under uncertainty A novel vehicle routing problem for vaccine distribution using SIR epidemic model A decision support system for demand management in healthcare supply chains considering the epidemic outbreaks: A case study of coronavirus disease 2019 (COVID-19) A network flow model for inventory management and distribution of influenza vaccines through a healthcare supply chain. Operations Research for Health Care Redesign of vaccine distribution networks Cold chain transportation decision in the vaccine supply chain Modeling for the equitable and effective distribution of food donations under stochastic receiving capacities Modeling for the equitable and effective distribution of donated food under capacity constraints Two decades of vaccine innovations for global public good: Report of the developing countries' vaccine manufacturers network 20th meeting An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine Cold supply chain design with environmental considerations: A simulationoptimization approach Distributional trade-offs between regionally equitable and cost-efficient allocation of renewable electricity generation Optimizing vaccine distribution networks in low and middleincome countries A chance constrained fuzzy goal programming approach for perishable pharmaceutical supply chain network design Acknowledgements Dr. Madjid Tavana is grateful for the partial support he received from the Czech Science Foundation (GAˇCR19-13946S) for this research. Conflict of interest The above authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.